You are here

Xiidra

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

CP WIre

Bristol Myers Squibb

executive compensation

Flag link:

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

Bristol Myers Squibb

executive compensation

Flag link:

After $3.4B deal and EU withdrawal, Novartis looks to sell Xiidra

After $3.4B deal and EU withdrawal, Novartis looks to sell Xiidra

Fierce Pharma

Flag link:

Two biotechs target dry eye disease after Novartis’ Xiidra problems

Two biotechs target dry eye disease after Novartis’ Xiidra problems

Pharmaforum

dry eye disease

Azura Ophthalmics

Flag link:

Novartis introduces inflammatory villain in its first Xiidra dry eye DTC campaign

Novartis introduces inflammatory villain in its first Xiidra dry eye DTC campaign

Fierce Pharma

DTC advertising

dry eye disease

Flag link:

Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra

Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra

Endpoints

dry eye disease

Flag link:

Novartis strikes out with dry eye med Xiidra in Europe

Novartis strikes out with dry eye med Xiidra in Europe

Seeking Alpha

dry eye disease

Flag link:

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Endpoints

Oyster Point Pharma

dry eye disease

Flag link:

Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra

Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra

Pharmaceutical Business Review

hdry eye disease

Flag link:

Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal

Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal

Fierce Pharma

dry eye disease

Flag link:

Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt

Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt

Bloomberg

Flag link:

Hoping to shake Allergan/Shire’s dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug

Hoping to shake Allergan/Shire’s dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug

Endpoints

dry eye disease

Flag link:

Ocugen’s Dry Eye Disease Therapy Could Compete with Allergan and Shire

Ocugen’s Dry Eye Disease Therapy Could Compete with Allergan and Shire

Xtalks

dry eye disease

Flag link:

Shire's DTC move to scrap smiling patients for double 'i's pays off—and it thinks other pharmas should take note

Shire's DTC move to scrap smiling patients for double 'i's pays off—and it thinks other pharmas should take note

Fierce Pharma

dry eye disease

Flag link:

Allergan Is Losing Its No. 2 Product More Rapidly Than Expected

Allergan Is Losing Its No. 2 Product More Rapidly Than Expected

Seeking Alpha

dry eye disease

Flag link:

Allergan's Restasis Faces Dry Eye Threat: Examining XIIDRA's Initial Sales Trends

Allergan's Restasis Faces Dry Eye Threat: Examining XIIDRA's Initial Sales Trends

Seeking Alpha

dry eye disease

Flag link:

Shire wants consumers and their eyes to be 'Friends'

Shire wants consumers and their eyes to be 'Friends'

BioPharma Dive

celebrity endorsements

dry eye disease

Flag link:

Shire taps Jennifer Aniston for awareness campaign as it enters the eye care market

Shire taps Jennifer Aniston for awareness campaign as it enters the eye care market

Medical Marketing and Media

dry eye disease

celebrity endorsements

Flag link:

In the Spirit of the Olympics: On and Off the Pharma Podium

In the Spirit of the Olympics: On and Off the Pharma Podium

PharmExec

Valeant Pharmaceuticals

Flag link:

The Shire Vs. Allergan War Has Begun

The Shire Vs. Allergan War Has Begun

Seeking Alpha

dry eye disease

Flag link:

Pages